RenovoRX (NASDAQ:RNXT) has announced that an abstract presented at the ASCO Gastrointestinal Cancers Symposium 2025 highlights promising pharmacokinetic (PK) data from its patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform for treating locally advanced pancreatic cancer (LAPC).
The abstract was presented by Paula Novelli, MD, principal investigator of the TIGeR-PaC trial at the University of Pittsburgh Medical Center. Dr. Novelli and her co-authors presented a study titled, Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial, which is a sub-study of RenovoRx’s ongoing pivotal Phase III TIGeR-PaC clinical trial in LAPC.
Dr. Novelli remarked, “Pancreatic cancer remains one of the most challenging cancers to treat, and this new data further highlights the potential of RenovoRx’s TAMP therapy platform as a transformative therapeutic option.”
“TAMP is intended to direct a drug and more effectively target the tumor while minimizing systemic impact, and this sub-study shows that despite delivering more gemcitabine in a shorter time, the total systemic drug exposure was significantly lower compared to intravenous treatment. This data further demonstrates that TAMP has the potential to deliver gemcitabine to the tumor more efficiently, enhancing local treatment effectiveness while reducing the broader impact on the body, ultimately minimizing the systemic side effects of chemotherapy,” she added.
